- 30-04-2018GDPR Changes. Tell Us How You Want to Be Contacted.
- 10-04-2018EGA Board Membership Opportunities
- 10-04-2018Advocacy Training Grant
- 07-02-2018Important Changes to Data Protection.
Many physicians and scientists have played an active role in supporting and encouraging the work of patient groups. In 1994 the first meeting of the European Working Group on Gaucher Disease (EWGGD) was held in Trieste, Italy, and representatives of the known European patient groups including the Israeli Gaucher Association were invited to join with the doctors and scientists.While the patient representatives understood relatively little of the detailed science discussed, their presence was seen to encourage the professionals.
Patient representatives continued to attend EWGGD meetings in Maastricht, Holland, in 1997 and in Lemnos, Greece in 1999. During these meetings, the patient representatives took time to discuss their own priorities and concerns. It became apparent that the patient groups needed more time for discussion and at the fourth EWGGD meeting in Jerusalem, Israel (2000), a separate day was set aside for a special European Gaucher Alliance (EGA) meeting. At subsequent EWGGD meetings in Prague, Czech Republic (2002); Barcelona, Spain (2004); Cambridge, UK (2006); Budapest, Hungary (2008); Cologne, Germany (2010); Paris, France (2012); Haifa, Israel (2014 and Zaragoza, Spain (2016) the EGA held their own separate meetings to discuss issues of common interest.
Together with patient representatives from Russia, Ukraine, Bulgaria and Romania the EGA took on the role of negotiating for humanitarian aid with the Genzyme Corporation and in 2004, the company agreed the European Cerezyme Access programme which provides free treatment for severely affected patients whose health services cannot or will not meet the cost of treatment, to date 117 patients in 14 countries receive treatment through ECAP, the ECAP programme has now been incorporated in the International Cerezyme Access programme (INCAP).
At the EWGGD meeting in Budapest in June 2008, members of the EGA voted to become a formal constituted organisation and elected a formal board of directors. The EGA has since become an incorporated limited company registered in England.
In June 2016, during the biennial EGA Meeting in Zaragoza, members voted for the EGA to become a global organisation. Since then, all members, regardless of their country of origin, have the same rights.
The EGA has an office in England that provides administrative support and underpins the work of the directors.